Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

Adocia SA

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

AB Science S.A.

Amolyt Pharma is a biopharmaceutical company focused on developing treatments for hypoparathyroidism, a rare endocrine disorder. The company is developing eneboparatide, a novel parathyroid hormone receptor 1 (PTHR1) agonist, which has demonstrated promising results in clinical trials.

Thierry Abribat

Amolyt Pharma

BIOMUNEX is a biopharmaceutical company focused on discovering and developing differentiated immunotherapeutic approaches to address unmet medical needs in oncology. They are committed to providing game-changing immunotherapies for solid tumors and hematological malignancies using their proprietary BiXAb® bi- and multispecific antibodies.

Pierre-Emmanuel Gerard

BIOMUNEX

Adocia is a clinical-stage biotechnology company specialized in the development of innovative treatments for diabetes and obesity.

Adocia

ADOCIA | 10,583 followers on LinkedIn. &quot;Innovative medicine for everyone, everywhere&quot;​ | &quot;Innovative medicine for everyone, everywhere&quot;​ 

Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. 

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

Investor, Advisor, Board Member

Mads Dall

Claire Mégret

Director of Innovation & Physico-Chemistry Department ADOCIA

Emmanuel Dauty

Head of Process Chemistry Development at ADOCIA

Guilhem Mora

ADOCIA

#ETUDE | Dépôts de brevets et innovation : focus sur la dynamique portée par les #PME françaises 🇫🇷 On recense environ 159 000 PME en France qui sont essentielles dans le paysage de l'innovation, notamment dans les technologies avancées 🚀 Le ratio pour les PME est de 1 brevet pour 3 millions d’euros investis en R&D 💶 Malgré une stagnation de leurs publications depuis 2019, 80 % des demandes de cette catégorie d’entreprise proviennent de petites PME, souvent des  #startups dynamiques. Celles âgées de 5 à 19 ans représentent la moitié des dépôts, démontrant une forte capacité d’innovation et de résilience 🛡️ Le portefeuille des brevets en vigueur des PME a augmenté de 11% depuis 2020 ↗️ 44% des demandes de brevets en technologie médicale proviennent des PME ⚕️ Ci-dessous le palmarès des 15 premières PME déposantes de brevets depuis 2019 ⤵️ En savoir plus 👉 https://bit.ly/3NYmTCg Téléchargez l'étude : 🔗 https://bit.ly/40ApHwZ Aledia | Isorg | SuperGrid Institute | IRT b-com | Petzl | IRT Jules Verne | WHYLOT | FOGALE Sensors | CPE Lyon | PKvitality | Aryballe | Tallano Technologies | IRT AESE - Saint Exupéry | NAOS Medical (Bioderma - Institut Esthederm - Etat Pur) | ADOCIA | eLichens | BIORET CORP | ITEN - Solid-state micro-batteries | Moving Magnet Technologies (MMT)

INPI France

🤝 ADOCIA is heading north for #partnering ! Join Mathieu-William Gilbert , Adocia COO-CFO, and Jeremy Benattar , Head of Marketing & Strategy, at #BIOEurope , November 4–6, 2024, in Stockholm, Sweden. The event marks 30 years of facilitating partnerships by EBD Group . It's not too late to request a meeting with them if you're interested in learning more about our latest innovations (hormonal combinations, long-acting injectables, oral delivery of peptides, cell delivery and much more!): ➡️ Request a meeting: https://lnkd.in/edKBRYf See you in Stockholm? #Biotech #LAI #OralDelivery #CellTherapy #Diabetes #Obesity

Merci Stéphanie Maugey - Brunelle pour cette belle mise en lumière ! 👍

🚀 ADOCIA is thrilled to announce its participation in the “Partnership Opportunities in Drug Delivery” (PODD) Conference! 🚀 Emmanuel Dauty , Adocia Director of #Innovation , will be showcasing our innovative technology platforms to potential partners: ♦️ #AdoGel , for sustained release of peptides is designed as a solution to reduce patient burden. Applied to #semaglutide , we achieved a release lasting over one month! ♦️ #AdoShell , a unique approach to cell delivery and is currently being applied to islets of Langerhans. ♦️ #AdOral , our solution to improve the bioavailability of peptides for oral delivery. ♦️ And of course, our historical #BioChaperone ®, designed to combine and stabilize incompatible hormones to treat obesity and diabetes, with the most recent applications to #cagrilintide and #semaglutide . 📅 Event Date: October 28-29, 2024 📍 Location: Boston, MA ➡️ For more info: https://lnkd.in/gQ_wSyBb If you're attending, be sure to connect with Emmanuel Dauty to explore our cutting-edge science and discover how our innovations could be the solution to your toughest drug delivery challenges! #PODD2024 #DrugDelivery #BioChaperone #Obesity #Diabetes #Innovation #SustainedRelease

[Press Release] 📰 Today, ADOCIA proudly announces the patenting of stable combinations of #GLP -1 and #amylin analogs for treating obesity and diabetes using our innovative #BioChaperone ® platform. Once more, the BioChaperone® platform has demonstrated its capability to "mix the unmixable", delivering a stable formulation of #semaglutide combined with #cagrilintide ("CagriSema"), hormones that are otherwise incompatible. This resulting combination could be administered through all standard subcutaneous injection devices, including multi-use, achieving one goal: to treat more patients, at constant manufacturing capacities, thereby adressing the exploding demand for obesity and diabetes products. #Biotech #Peptides #Diabetes #Obesity #Adocia #Innovation

[IR Event] Olivier Soula, CEO of ADOCIA , and Mathieu-William Gilbert , COO-CFO, will participate in the Portzamparc Groupe BNP Paribas ’ "Biotech and Health" digital seminar, on October 8 - 9, 2024. 📅 On October 9, 3:30 PM - 4:15 PM, they will have the opportunity to discuss with the investor community our latest advances and our strategic perspectives. #Investments #Investors #Biotech

🚀 ADOCIA is excited to announce our participation in #CPHI Milano 2024, from October 8th to 10th. We’re using this opportunity to meet with industry professionals, strengthen existing collaborations, and explore new prospects for our projects. 🧫 One of our focuses is securing essential components for our cell therapy program - AdoShell Islets - as we prepare for our first in-human trial, expected next year. 🏥 We look forward to productive discussions and new opportunities at CPHI Milano! Feel free to contact David Rigal , Pharmaceutical Development Director, Charles Fortier , Senior Research Scientist in Drug Product Development, or Jeremy Benattar , Head of Marketing Strategy, to schedule a meeting or simply for a chat! #CPHIMilano #AdoShellIslets #FirstInHumanTrial #Networking #Biotech

🛬 Mathieu-William Gilbert , just back from the Forum LYON POLE BOURSE , is now in Amsterdam to participate in #Pharmageddon EU 2024! After launching in 2023 by Impatient Health , Pharmageddon set out to revolutionize pharma by creating a space where creative and innovative minds can collaborate. With a commitment to action, not just discussion, this two-day event aims to deconstruct and rebuild the industry. At 5:00 p.m. CEST, he will join a dynamic panel on Proactive Health Equity, alongside industry leaders Marijn Verhoef and Olivia Kager . This panel will dive deep into the next chapter of health equity, focusing on how we can not just react but anticipate and eliminate access barriers before they arise. By leveraging insights to ensure that healthcare solutions reach everyone, this conversation aims to drive both social impact and open new commercial pathways. ➡ For more information: https://lnkd.in/eWmSAY8E #PharmageddonEU #HealthEquity #Innovation #Inclusion #HealthcareTransformation #FutureOfPharma

[Press Release] 📃 ADOCIA Announces Appointment of Mathieu-William Gilbert as Chief Financial Officer Mathieu-William Gilbert will serve as Chief Financial Officer in addition to his position as Chief Operating Officer, which he has held since May 2024. Valérie Danaguezian , who has held the position of #CFO since Adocia’s founding in 2005, is leaving the company to focus on a family project. Mathieu-William Gilbert joined the Company following a distinguished career of more than fifteen years at Novo Nordisk, where he held #VicePresident and #GeneralManager positions for several subsidiaries. In his expanded role, Mathieu-William Gilbert will oversee administrative and #financial functions, #investor relations, #legal affairs, and #HumanResources . He is also a member of the #Executive Committee and serves as #SecretaryGeneral of the Board of Directors. Mathieu-William Gilbert , welcome to the team 🙌 Valérie Danaguezian , we wish you all the success in your new endeavors!! 💟 ➡ Find out more on the full Press Release: https://lnkd.in/ecskKmq5

🚀 Demain, retrouvez ADOCIA lors du Forum LYON POLE BOURSE ! L'équipe dirigeante d'Adocia, rassemblant Olivier Soula, Valérie Danaguezian , et Mathieu-William Gilbert , se joint à cet évènement annuel incontournable pour entretenir les relations et échanger avec un réseau de plus de 120 investisseurs ! 📅 Date : mardi 24 septembre 📍 Lieu : Palais du Commerce - Place de la Bourse - 69002 Lyon Pour plus d’informations 👉 https://lnkd.in/fyiEkUS #LyonPoleBourse #Investissement #Financement #Bourse #Innovation

Metric
Company Name	Adocia SA	AB Science S.A.	Amolyt Pharma	BIOMUNEX
Symbol	ADOC	AB
MSH ID	COM:ADOCIA	COM:AB-SCIENCE	COM:AMOLYTPHARMA	COM:BIOMUNEX
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	8	Healthcare & Health Services
Industry	Biotechnology	Drug Manufacturers - Specialty & Generic	Healthcare & Health Services	Biopharmaceuticals
Country	FR	FR	FR
Stage	Post-IPO Debt		Series
Employee Count	78	51	61	1
Website	adocia.com	ab-science.com	amolytpharma.com	biomunex.com
LinkedIn	adocia		amolytpharma
Founders

Metric
Market Cap	100.30M	61.06M
Enterprise Value
Monthly Web Traffic	521	690	539
Web Traffic Growth	-0.54	-0.89	-0.86
Valuation
Raised Capital	6.96M		138.63M

Metric
Revenue	2.27M	1.02M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-18.95M	620.01K
EBITDA	-18.09M	-5.77M
Operating Income	-18.61M	-14.18M
Net Income	-22.35M	-10.61M
EPS	-2.02	-0.21
Diluted EPS	-2.02	-0.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-2.44	-0.30
Operating Profit Margin	-2.49	-13.13
EBITDA Margin	-7.96	-5.64
Net Profit Margin	-2.76	-8.80
Return on Equity	3.60	0.91
Return on Assets	-1.08	-0.42
Return on Capital Employed	4.03	-1.68

COM:ADOCIA

Adocia

Last Close

8.13

25/11 09:23

Market Cap

94.95M

Beta: -

Volume Today

25.12K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-11.60	-10.63
P/B Ratio	-6.17	-4.06
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	35.40	167.28
EV Multiple	-2.91	-1.78

Metric
Days Sales Outstanding	275.72
Days Payables Outstanding	745.68	86.68K
Days Inventory Outstanding	9.81	95.78
Operating Cycle	823.59	7.34K
Cash Conversion Cycle	776.31	5.56K
Asset Turnover	0.53	0.07

Metric
Operating Cash Flow	-5.23M	-17.82M
Free Cash Flow	-5.39M	-18.18M
Cash Flow to Debt	-0.46	-0.89
Operating Cash Flow/Sales	-1.27	-8.90
Free Cash Flow Yield	-0.11	-0.12

Metric
Cash & Equivalents	13.69M	6.41M
Accounts Receivable	1.23M
Inventory	287.29K	354.89K
Goodwill
Debt to Capitalization	2.81	135.44
Debt to Assets	1.08	1.00
Current Ratio	1.05	0.90
Quick Ratio	1.01	1.41

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.14
R&D to Revenue		13.93
SG&A to Revenue		1.95